SEC Form 4 · accession 0001437749-16-023242
Stablecoin Development Corp · SDEV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark M Sieczkarek
Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 7:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001389545
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F3,F2 | $2.02 | Jan 4, 2016 | A | 16,032 | A | Jan 4, 2016 | Jan 4, 2026 | Common Stock | 16,032 | 23,246 | D |
Explanation of responses
- F1Granted pursuant to the 2007 Omnibus Incentive Plan and the 2016 Non-Employee Director Compensation Plan
- F2Stock options will vest in equal monthly installments over one year starting from the date of grant
- F3On December 18, 2015, the common stock of NovaBay Pharmaceuticals reverse split 1-for-25, and is reflected accordingly in both the number of underlying option shares and exercise price of the award.